Cytokinetics, Incorporated

NasdaqGS:CYTK Stock Report

Market Cap: US$5.4b

Cytokinetics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:CYTK Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
17 Mar 25SellUS$123,155Andrew CallosIndividual2,775US$44.38
17 Mar 25SellUS$1,677,568Robert BlumIndividual37,648US$44.65
17 Mar 25SellUS$194,784Fady MalikIndividual4,389US$44.38
13 Mar 25SellUS$1,167,751Andrew CallosIndividual26,771US$43.62
06 Mar 25SellUS$356,026Fady MalikIndividual8,228US$43.27
06 Mar 25SellUS$737,177Robert BlumIndividual16,970US$43.44
06 Mar 25SellUS$144,565Andrew CallosIndividual3,341US$43.27
05 Mar 25SellUS$1,455,650Robert BlumIndividual33,743US$43.23
04 Mar 25SellUS$38,250Robert HarringtonIndividual900US$42.50
03 Mar 25SellUS$105,013Fady MalikIndividual2,449US$42.88
03 Mar 25SellUS$47,768Andrew CallosIndividual1,114US$42.88
10 Dec 24SellUS$101,300Fady MalikIndividual2,000US$50.65
26 Nov 24SellUS$100,280Fady MalikIndividual2,000US$50.14
12 Nov 24SellUS$60,936Fady MalikIndividual1,042US$58.48
30 Oct 24SellUS$103,860Fady MalikIndividual2,000US$51.93
15 Oct 24SellUS$108,400Fady MalikIndividual2,000US$54.20
01 Oct 24SellUS$104,220Fady MalikIndividual2,000US$52.11
17 Sep 24SellUS$113,520Fady MalikIndividual2,000US$56.76
03 Sep 24SellUS$118,830Fady MalikIndividual2,084US$57.02
20 Aug 24SellUS$112,460Fady MalikIndividual2,000US$56.23
06 Aug 24SellUS$107,400Fady MalikIndividual2,000US$53.70
23 Jul 24SellUS$114,040Fady MalikIndividual2,000US$57.02
10 Jul 24SellUS$311,245Robert BlumIndividual5,733US$54.29
09 Jul 24SellUS$111,780Fady MalikIndividual2,000US$55.89
05 Jul 24SellUS$13,816Robert HarringtonIndividual253US$54.61
01 Jul 24SellUS$621,575Robert BlumIndividual11,500US$54.05
25 Jun 24SellUS$107,480Fady MalikIndividual2,000US$53.74
17 Jun 24SellUS$1,183,391Robert BlumIndividual22,500US$52.60
11 Jun 24SellUS$125,469Fady MalikIndividual2,366US$53.03
10 Jun 24SellUS$104,140Muna BhanjiIndividual2,000US$52.07
03 Jun 24SellUS$635,978Robert WongIndividual13,011US$48.88
03 Jun 24SellUS$76,851Robert HarringtonIndividual1,580US$48.64
09 Apr 24SellUS$297,280Fady MalikIndividual4,000US$74.32

Insider Trading Volume

Insider Buying: CYTK insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of CYTK?
Owner TypeNumber of SharesOwnership Percentage
State or Government44,8660.0337%
Private Companies105,8840.0795%
Individual Insiders571,5610.429%
Institutions132,510,82599.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 82.89% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.1%
BlackRock, Inc.
15,469,312US$702.8m1.42%0.01%
11.3%
T. Rowe Price Group, Inc.
13,377,204US$607.7m4.06%0.05%
10.1%
The Vanguard Group, Inc.
11,915,821US$541.3m1.31%0.01%
9.12%
FMR LLC
10,794,227US$490.4m-10.8%0.03%
6.66%
Wellington Management Group LLP
7,888,697US$358.4m1.46%0.06%
5.21%
State Street Global Advisors, Inc.
6,167,340US$280.2m-4.51%0.01%
2.4%
Geode Capital Management, LLC
2,841,338US$129.1m-0.25%0.01%
2.3%
RTW Investments, LP
2,721,158US$123.6m0%1.7%
2.11%
Deep Track Capital, LP
2,500,000US$113.6m297%4.04%
1.98%
Vestal Point Capital, LP
2,350,000US$106.8m56.7%6.22%
1.86%
Polar Capital Holdings Plc
2,196,721US$99.8m-6.04%0.35%
1.82%
Marshall Wace LLP
2,153,313US$97.8m14.9%0.14%
1.61%
Pictet Asset Management Limited
1,911,999US$86.9m-8.45%0.06%
1.35%
AllianceBernstein L.P.
1,595,324US$72.5m-3.95%0.02%
1.34%
OrbiMed Advisors LLC
1,584,005US$72.0m107%1.08%
1.28%
UBS Asset Management AG
1,517,249US$68.9m161%0.01%
1.24%
Northern Trust Global Investments
1,471,489US$66.8m10.7%0.01%
1.16%
Citadel Advisors LLC
1,371,645US$62.3m46.4%0.06%
1.13%
Charles Schwab Investment Management, Inc.
1,335,189US$60.7m1.04%0.01%
1.11%
Armistice Capital LLC
1,312,000US$59.6m-30.8%1.38%
1.08%
Westfield Capital Management Company, L.P.
1,279,990US$58.2m5.53%0.26%
0.96%
Melqart Asset Management (Uk) Ltd
1,136,434US$51.6m-6.25%7.03%
0.93%
Capital Research and Management Company
1,096,164US$49.8m872%no data
0.92%
Pentwater Capital Management LP
1,090,000US$49.5m-0.91%0.88%
0.91%
Brown Advisory Incorporated
1,075,872US$48.9m-7.68%0.06%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 16:50
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cytokinetics, Incorporated is covered by 40 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Jason ZemanskyBofA Global Research
Mayank MamtaniB. Riley Securities, Inc.